Skip to main content
ABCL logo

ABCL · AbCellera Biologics Inc. · Investor Relations

Track ABCL — free
$10.47 -0.55 (-4.99%) At close · Nov 19 Play latest call Q3 2026 earnings call transcript
Market Cap
$3.42B
Shares
326.62M
Volume · Nov 19 2.5M Avg daily vol (3M) 4.38M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-09 AbCellera Reports Q3 2026 Business Results
2026-11-05 AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
2026-10-22 AbCellera to Present at Upcoming Investor Conferences in November 2026
2026-10-08 AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
2026-10-01 AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
2026-09-16 AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
2026-09-02 AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
2026-08-13 AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-08-11 AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-08-10 AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
2026-08-07 AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
2026-08-05 AbCellera Reports Q2 2026 Business Results
2026-07-29 AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
2026-07-07 AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-06 AbCellera Appoints Dr. Lynn Seely to its Board of Directors
2026-06-17 Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
2026-06-05 AbCellera Appoints Dr. Victor Sandor to its Board of Directors
2026-05-11 AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
2026-05-07 AbCellera to Present at Upcoming Investor Conferences in May and June 2026
2026-04-20 AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
2026-04-01 AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
2026-02-24 AbCellera Reports Full Year 2025 Business Results
2026-02-11 AbCellera to Present at Upcoming Investor Conferences in March and April 2026
2026-01-22 AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
2026-01-12 AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Past events

Date Event Type
2026-11-17 UBS Global Biopharma Conference Conference
2026-11-16 Jefferies Global Healthcare Conference Conference
2026-11-16 Jefferies Global Healthcare Conference in London Conference
2026-11-11 Stifel Healthcare Conference Conference
2026-11-09 AbCellera Biologics Inc. Q3 FY2026 Earnings Call Earnings call
2026-09-09 Cantor Global Healthcare Conference Conference
2026-08-10 AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Earnings call
2026-08-05 AbCellera Biologics Inc. Q2 FY2026 Earnings Call Earnings call
2026-06-04 Jefferies Global Healthcare Conference in New York Conference
2026-05-14 Bank of America Health Care Conference Conference
2026-05-11 Q1 2026 Earnings Results and Business Update Earnings call
2026-04-21 2026 Bloom Burton & Co. Healthcare Investor Conference Conference
2026-03-17 KeyBanc Capital Markets Healthcare Forum Event
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2026-02-24 FY 2025 Earnings Results and Business Update Earnings call
2026-01-14 44th Annual JP Morgan Healthcare Conference Conference
2025-12-03 Piper Sandler Healthcare Conference Conference
2025-11-20 Jefferies Global Healthcare Conference Conference
2025-11-13 Stifel Healthcare Conference Conference
2025-11-06 Q3 2025 Earnings Results and Business Update Earnings call
2025-11-06 Truist Securities BioPharma Symposium Event
2025-09-08 Morgan Stanley 23rd Annual Global Healthcare Conference Conference
2025-09-05 2025 Wells Fargo Healthcare Conference Conference
2025-08-07 Q2 2025 Earnings Results and Business Update Earnings call
2025-06-09 Goldman Sachs 46th Annual Global Healthcare Conference Conference

Source: https://investors.abcellera.com/overview/default.aspx

Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 173 filings 162 filers Visit website Investor relations